Navigation Links
New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohn's Patients
Date:10/26/2009

uid stools per day, during the previous 24 hours before the assessment. Each item is scored from 0 to 3 and total scores of less than or equal to 4 signify remission. Most reported adverse events were of mild to moderate intensity. The most serious adverse events (some leading to death) reported were exacerbation of Crohn's disease, serious infections (3 of which were tuberculosis) and malignancies. (Abstract #P716)

In the original PRECiSE 2 trial, moderate to severe Crohn's patients who responded to CIMZIA after an open-label induction phase were randomized to receive CIMZIA or placebo and evaluated for maintenance of clinical response by week 26, of which a significant majority (62 percent) of CIMZIA treated patients maintained their overall clinical response compared to placebo (34 percent, p<0.001). In the separate post-hoc analysis of the PRECiSE 2 trial, three patient-reported Crohn's Disease Activity Index (CDAI) components (number of loose/liquid stools, abdominal pain, and general well-being) were examined from baseline (day 0) to day 8 to 14, comparing week 6 responders and nonresponders to CIMZIA treatment. The CDAI is a patient/physician questionnaire which incorporates eight CD-related variables. Patients completed a diary card daily for 7 days prior to each clinic visit. Scores of <150 indicate remission and scores of >450 indicate severe illness along the 600 point scale. There was a 31 percent (95% CI: -1.7, -1.2) reduction of mean number of loose/liquid stools among responders versus a 14 percent (95% CI: -1.0, -0.3) reduction for nonresponders by day 8. Twenty percent of CIMZIA responders reported no abdominal pain by day 8 versus 16 percent of nonresponders (p= 0.002). Approximately 21 percent of CIMZIA responders reported improvement in general well-being scores versus 14 percent of nonresponders (p=0.001). (Abstract #P286)

"These data further underscore the value of CIMZIA as a therapeutic o
'/>"/>

SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
2. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
3. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
4. Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohns Disease
5. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
6. e-Zassi.com Provides Industry With Online U.S. FDA Regulatory Calculator for Rapid Medical Device Technology Assessment
7. Access Pharmaceuticals Provides Update on MuGard Commercial Launch and First European Clinicians Feedback
8. New ALS Patient Simulator Advanced Provides Valuable Training for EMS Teams and In-Hospital Emergency Personnel
9. CardioGenics Holdings Inc. Provides Update on FINRA Submission Regarding Name Change
10. Young Innovations, Inc. Provides Third Quarter Conference Call Details
11. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... and ,S-HERTOGENBOSCH, The Netherlands , ... subsidiary, HealthLink International received its ISO 13485 certificate for ... and administrative services for medical device manufacturers throughout ... Rick Hughes , President of HealthLink Europe and ... 13485 certified facilities, two in Europe ...
(Date:4/1/2015)... April 1, 2015  New York College of Health ... Intellectual Properties portfolio with U.S. Patent #8,996,098 donated by ... patent represents a surgical instrument that allows surgeons to ... it were in the traditional format of a slide ... medical databases during surgery, thus providing the surgeon real ...
(Date:4/1/2015)... YORK , April 1, 2015 Morgan ... claims against the board of directors of Auspex Pharmaceuticals, ... concerning possible breaches of fiduciary duty and other violations ... Company to Teva Pharmaceuticals Industries Ltd.  The transaction is ... own shares of Auspex and would like to learn ...
Breaking Medicine Technology:Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 2Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 3
... Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) ... VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, ... Phase 3 studies in patients with macular edema due ... 56.1 percent of patients receiving VEGF Trap-Eye 2 milligrams ...
... N.Y., Dec. 20, 2010 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... teleconference and webcast at 8:30 a.m. Eastern Time on Monday, ... study with VEGF Trap-Eye in central retinal vein occlusion (CRVO) ... DA VINCI study in patients with diabetic macular edema (DME). ...
Cached Medicine Technology:Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 2Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 3Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 4Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 5Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 6Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 7Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 8Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 9Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME) 2
(Date:4/2/2015)... Portsmouth, New Hampshire (PRWEB) April 02, 2015 ... the availability of ForMedical Cloud services, a comprehensive ... for use by home health care service organizations. ... a single source solution for the provisioning and ... a high quality and competitively positioned home health ...
(Date:4/2/2015)... 02, 2015 Deerfield Veterinary Hospital ... accreditation from the American Animal Hospital Association (AAHA). ... to 15 percent of veterinary practices in the ... hospitals are not required by law to be ... examined the Springfield veterinary hospital  on some ...
(Date:4/2/2015)... Atlanta, Georgia (PRWEB) April 02, 2015 ... continued the Lunch Seminar Series on March 30th ... Director of PartnerTech Inc. , a leading provider ... ‘Total Cost Thinking: Defining Total Cost vs. Piece ... late-stage configuration, agile supply chain service and other ...
(Date:4/2/2015)... “ SmartenFit ” was featured on NewsWatch ... at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... for a sustainable healthy lifestyle. , Health and fitness apps ... new application that covers health from a different angle. The ...
(Date:4/2/2015)... 02, 2015 Zapable - a new ... a quick and easy means for creating professional mobile ... creating a buzz of excitement throughout the Internet marketing ... attention of HonestyFirstReviews.com’s Tiffany Hendricks, prompting her to publish ... Andrew and Chris Fox's new Zapable software has ...
Breaking Medicine News(10 mins):Health News:ChartaCloud Introduces ChartaCares and ForMedical Cloud Services for Home Health Care 2Health News:Deerfield Veterinary Hospital Earns Renewed AAHA Accreditation 2Health News:Georgia Tech Manufacturing Institute Lunch Series Continues with Gary Bruce of PartnerTech 2Health News:Georgia Tech Manufacturing Institute Lunch Series Continues with Gary Bruce of PartnerTech 3Health News:An Application for Long Term Sustainable Lifestyle Change Was Featured on NewsWatch Television 2Health News:Zapable - Review Examining Andrew and Chris Fox’s App Building Software System Released 2
... price for a 30-second advertising spot in the 2012 Super Bowl ... study suggests that, for advertisers, it may not really matter if ... But for the sake of companies forking out big bucks on ... The study by an Oregon State University researcher, which is ...
... -- Teens who think of themselves as thrill-seekers and who ... likely to drive with other teens in the car, which ... finds. And a second study of teens involved in ... distraction and risky driving behavior often played a role. ...
... HealthDay Reporter , THURSDAY, Jan. 26 (HealthDay News) -- ... provide insight into whether patients are at high risk of ... cancer. The test, which is currently available, could ... prevent the cancer from returning. There are caveats: The ...
... a "common sense" decision to start the company in a ... belt. , "We wanted to give better stroke care," said ... of Neurology at the Medical College of Georgia at Georgia ... and his colleagues were frustrated that nearly five years after ...
... By Denise Mann HealthDay Reporter , THURSDAY, Jan. ... for liver cancer among people with hepatitis B, a new study ... hepatitis B virus, is one of the main causes of liver ... have shown promise in reducing risk for cancer. Other studies have ...
... a sensitive non-invasive marker of early lung disease in young ... from Australian researchers. "We found that LCI is elevated ... airway inflammation and Pseudomonas aeruginosa," said Yvonne Belessis, MBBS, MPH, ... may not only be a marker of early CF lung ...
Cached Medicine News:Health News:Sporting event ads viewed favorably - especially if the game is close 2Health News:Teen Driver's Friends Can Be Dangerous Distraction, Studies Find 2Health News:Test Might Predict Risk of Lung Cancer's Return 2Health News:Georgia Bio honors biotech company that enables stroke care 2Health News:Georgia Bio honors biotech company that enables stroke care 3Health News:Statins May Stave Off Liver Cancer in People With Hepatitis B 2Health News:Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index 2
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: